文献速递脊柱关节炎

古利木单抗治疗早期中轴型脊柱关节炎的疗效与肠道炎症的关系:一项早期缓解诱导研究

Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study.
PubMed 文献 · Arthritis Rheumatol · 2025-11-11

GO-GUT试验在58例病程不足一年且疾病活动的未治早期中轴型脊柱关节炎患者中,先以两种非甾体抗炎药最优剂量治疗4周,未达标者升级为古利木单抗50 mg每4周一次,直至持续临床缓解。61.8%患者达到持续临床缓解,与肠道炎症无关;停药后78.1%患者在一年内复发。

要点

  • 58例未治早期axSpA患者中,72.7%需升级至古利木单抗治疗。
  • 61.8%患者达到持续临床缓解,与微观肠道炎症无关。
  • 停药后78.1%患者在一年内疾病复发。

核心结论

  • 在未治早期axSpA中应用达标治疗策略可诱导高比例的持续临床缓解,无论是否存在微观肠道炎症。

研究设计与样本

  • GO-GUT(NCT03270501)为前瞻性、开放标签、52周试验,纳入病程不足一年且疾病活动的未治axSpA患者58例。
  • 基线行回结肠镜及肠道黏膜组织病理学评估,所有患者先接受两种不同非甾体抗炎药最优剂量治疗4周。
  • 未达到无活动性疾病(ASDAS-CRP<1.3)或临床重要改善(ΔASDAS-CRP≥1.1)导致低疾病活动度(ASDAS-CRP<2.1)者,起始古利木单抗50 mg每4周一次单药治疗。
  • 观察到持续临床缓解(间隔12周连续两次访视ASDAS-CRP<1.3)或试验结束;达到持续临床缓解后停用所有药物并评估无药缓解可能性。

主要发现

  • 58例患者中28.6%存在微观肠道炎症,以急性炎症为主。
  • 72.7%患者需要升级至古利木单抗治疗。
  • 61.8%患者达到主要研究终点持续临床缓解,与肠道炎症无关。
  • 停药后78.1%患者在一年内疾病复发。

关键数值与推荐

  • 无活动性疾病定义为ASDAS-CRP<1.3。
  • 临床重要改善定义为ΔASDAS-CRP≥1.1且导致低疾病活动度(ASDAS-CRP<2.1)。
  • 持续临床缓解定义为间隔12周连续两次访视ASDAS-CRP<1.3。
  • 古利木单抗剂量为50 mg每4周一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of tight-control, rapid escalation to tumor necrosis factor inhibition in early axial spondyloarthritis (axSpA) in relation to gut inflammation. METHODS: GO-GUT (NCT03270501) was a prospective, open-label, 52-week trial in treatment-naïve patients with axSpA with less than one year of symptom duration and high disease activity. At baseline, patients underwent ileocolonoscopy with histopathological evaluation of the gut mucosa. Next, all patients received two different nonsteroidal anti-inflammatory drugs in optimal dose for a period of four weeks. If inactive disease, defined as Ankylosing Spondylitis Disease Activity Score (ASDAS) with CRP <1.3, or clinically important improvement (ΔASDAS-CRP ≥ 1.1) resulting in low disease activity (ASDAS-CRP <2.1) was not achieved, monotherapy with 50 mg golimumab every four weeks was initiated. Patients were observed until they achieved sustained clinical remission (ASDAS-CRP <1.3 at two consecutive visits with 12 weeks interval) or end of trial. Upon achievement of sustained clinical remission, all medication was discontinued, and the possibility of drug-free remission was evaluated. RESULTS: Fifty-eight patients were included in the trial. Microscopic gut inflammation was present in 28.6% of patients, which was predominantly acute inflammation. An escalation of therapy to golimumab was required for 72.7% of patients. The primary study endpoint of sustained clinical remission was reached by 61.8% of patients, irrespective of gut inflammation. Treatment discontinuation resulted in disease relapse within one year in 78.1% of patients. CONCLUSION: Applying a treat-to-target approach in treatment-naïve early axSpA allows to induce high rates of sustained clinical remission, regardless of the presence of microscopic gut inflammation.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Łukasik Z, De Craemer AS, Renson T, et al. Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study. Arthritis Rheumatol. 2025. PMID: 40524500. doi:10.1002/art.43283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。